Drugs promoting brain neuroplasticity are expected to be beneficial across multiple classes of brain ailments. Combination drugs – combining three FDA-approved drugs – can better address the wide range of damage that results from brain diseases and brain injuries. Our combination drugs are designed to promote cell repair/growth and boost the signaling between brain cells while also combating inflammation and cell damage and death from the inflammation (see discussion here).
Our first drug (NIV-001) has been engineered to promote remodeling, rewiring, and recovery after a patient has suffered a stroke. We expect our second drug (NIV-002) to address the impairments resulting from Traumatic Brain Injury and Concussion.
This condition has much in common with the damage resulting from stroke.
We foresee the need for neuroplastic-enhancing drugs in the fight against dementia and movement disorders, depression, immune system attacks, neuro/psychiatric disorders, and cognition deficits (see the list of potential targets). A healthy brain is critical to surviving but also thriving.